CEO Expands on Article from
How PlantPharm is Miles Ahead
The Federal Regulations regarding pharming have been the backbone of PlantPharm’s planning from the very beginning of our R&D work so there are no barriers to our operations at this stage of the company.
o PlantPharm created the first cGMP compatible system for documenting the production of plant-
o PlantPharm follows 21 CFR Part xxx and other Federal Regulations as they apply.
Our Biosafety Level 2 Laboratory and Pilot Plant operations were built, inspected and certified under USDA/APHIS & FDA regulations allowing PlantPharm to operate.
The United States Food and Drug Administration (FDA) acknowledged the first successful Human Clinical Trial using potatoes PlantPharm produced containing Hepatitis B antigen.
The FDA has authorized a second human clinical trial of our potato-
PlantPharm’s platform is a permanent expression platform vs. the transient expression platform that is used for the Tobacco plant technology. Also, no sexual degradation exists.
Massive yields have already been achieved in PlantPharm’s system. A conservative estimate would have yields in excess of 10 tons/acre/year of raw goods with oral delivery of finished product of at least 40%, far in excess of production from any other platform system.
PlantPharm’s Platform Technology can use plants to convert high-
Cost of production via PlantPharm will lower pharmaceutical prices significantly and quickly.
PlantPharm has identified 42 vaccines and 550 pharmaceuticals that can now be grown in plants, many as oral doses, for delivery using our Platform Technology.
Most competitors are still in the basic R&D stages most using bioreactors and are not yet commercialized while PlantPharm is ready to produce product for FDA licensing.
PlantPharm has been built on private funds with exception of NIH Grants that were used to prove the efficacy of the technology to the U.S. Health and Human Services.
Because PlantPharm has worked in stealth-
PlantPharm is preparing to build the most productive commercial-
July 19, 2019